Xinlu Liu, Xiaodong Tan, Peng Liu, Yunhao Wu, Songying Qian, Xiaobo Zhang

Oncology Research, Vol.26, No.7, pp. 1123-1131, 2018, DOI:10.3727/096504018X15166223632406

Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive tumors known, with an overall 5-year survival rate of less than 6% due to early local invasion and distant metastasis. Exploring suitable therapeutic targets associated with invasion and metastasis is required for improving the prognosis of PDAC. In this study, we investigated the role of the glycolytic enzyme phosphoglycerate mutase 1 (PGAM1) in PDAC. PGAM1 expression was examined in tissue samples of 54 PDAC patients using immunohistochemistry, and the correlation between clinicopathological expression and PGAM1 expression was determined. A survival curve was generated using the… More >

Qianren Xiao^*1, Lu Huang^†1, Zhongzu Zhang^‡1, Xiang Chen^*, Jiaquan Luo^*, Zhanmin Zhang^§, Shaoqing Chen^§, Yong Shu^*, Zhimin Han^*, Kai Cao^*

Oncology Research, Vol.25, No.2, pp. 267-275, 2017, DOI:10.3727/096504016X14732510786564

Abstract miRNAs play a pivotal role in the development and progression of osteosarcoma (OS). Previous studies indicated that miR-140 acts as a tumor suppressor in many cancers. However, its accurate expression and exact function in OS cells remain unknown. Herein, we demonstrated the lower expression of miR-140 in 40 paired OS tissues. Restoring miR-140 expression in OS cells had a marked effect on inhibiting cell proliferation and invasion, inducing cell apoptosis in vitro, and suppressing tumor growth in vivo. Moreover, a bioinformatics prediction indicated that the histone deacetylase 4 (HDAC4) is a target gene of miR-140 and More >